Anterix (NASDAQ:ATEX – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.39), Yahoo Finance reports. Anterix had a negative net margin of 217.80% and a negative return on equity of 18.84%. The business had revenue of $1.53 million for the quarter, compared to analysts’ expectations of $1.64 million. During the same quarter in the previous year, the firm earned ($0.11) EPS.
Anterix Stock Performance
NASDAQ ATEX traded down $0.21 on Friday, reaching $38.47. 21,679 shares of the stock traded hands, compared to its average volume of 124,830. Anterix has a 12 month low of $28.70 and a 12 month high of $42.41. The company has a market cap of $714.35 million, a price-to-earnings ratio of -78.94 and a beta of 0.86. The company has a fifty day moving average price of $36.48 and a 200-day moving average price of $34.48.
Analysts Set New Price Targets
Separately, JPMorgan Chase & Co. boosted their target price on shares of Anterix from $60.00 to $61.00 and gave the company an “overweight” rating in a research note on Thursday.
About Anterix
Anterix Inc operates as a wireless communications company. The company focuses on commercializing its spectrum assets to enable the targeted utility and critical infrastructure customers to deploy private broadband networks and innovative broadband solutions. It holds licensed spectrum in the 900 MHz band with coverage throughout the United States, Alaska, Hawaii, and Puerto Rico.
Further Reading
- Five stocks we like better than Anterix
- 3 Grocery Stocks That Are Proving They Are Still Essential
- The Cannabis Sector: Profitability Takes Center Stage
- Stock Average Calculator
- Amazon’s Stock Plunge: Is a Prime Buying Opportunity Knocking?
- How to Invest in Insurance Companies: A Guide
- Buy the Dip in e.l.f. Beauty: Analysts Point to a New High
Receive News & Ratings for Anterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anterix and related companies with MarketBeat.com's FREE daily email newsletter.